PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject “mid strength” dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia (CIN).
